ArticleJournal of medicinal chemistry2026
Structural Basis for BD1-Preferring 2,4-Disubstituted Pyrimidine BRDT Inhibitors.
Taimeng Liang, Xianghong Guan, Alice Chan, Prakriti Kalra, Rui Shi, Jonathan Solberg, Logan H Sigua, Jun Qi, William C K Pomerantz, Ernst Schönbrunn and 2 more
Abstract read
In one paragraphArticle in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Taimeng LiangDepartment of Chemistry, University of Minnesota, 207 Pleasant Street, SE, Minneapolis, Minnesota 55455-0431, United States.
Xianghong GuanDepartment of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, University of Minnesota College of Pharmacy, 717 Delaware Street, SE, Minneapolis, Minnesota 55414, United States.ORCID 0000-0002-7874-8065 Alice ChanDrug Discovery Department, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, Florida 33612, United States.
Prakriti KalraDepartment of Chemistry, University of Minnesota, 207 Pleasant Street, SE, Minneapolis, Minnesota 55455-0431, United States.
Rui ShiDepartment of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, University of Minnesota College of Pharmacy, 717 Delaware Street, SE, Minneapolis, Minnesota 55414, United States.
Jonathan SolbergDepartment of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, University of Minnesota College of Pharmacy, 717 Delaware Street, SE, Minneapolis, Minnesota 55414, United States.
Logan H SiguaDepartment of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, 360 Longwood Avenue, Boston, Massachusetts 02215, United States.
Jun QiDepartment of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, 360 Longwood Avenue, Boston, Massachusetts 02215, United States.ORCID 0000-0002-1461-3356 William C K PomerantzDepartment of Chemistry, University of Minnesota, 207 Pleasant Street, SE, Minneapolis, Minnesota 55455-0431, United States.ORCID 0000-0002-0163-4078 Ernst SchönbrunnDrug Discovery Department, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, Florida 33612, United States.ORCID 0000-0002-3589-3510 Jon E HawkinsonDepartment of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, University of Minnesota College of Pharmacy, 717 Delaware Street, SE, Minneapolis, Minnesota 55414, United States.ORCID 0000-0001-5461-7071 Gunda I GeorgDepartment of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, University of Minnesota College of Pharmacy, 717 Delaware Street, SE, Minneapolis, Minnesota 55414, United States.ORCID 0000-0002-8900-9460 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
The first bromodomain of the BET protein BRDT (BRDT-BD1) possesses a unique Arg54 residue at the terminus of the ZA channel, absent in other BET family members. We explored this structural uniqueness with 23 analogs of the BET/kinase inhibitor
Indexed as
Nuclear ProteinsPyrimidinesAnimalsBromodomain Containing ProteinsCrystallography, X-RayDogsHumansMadin Darby Canine Kidney CellsModels, MolecularStructure-Activity RelationshipBromodomain Containing ProteinsNuclear ProteinsPyrimidines
Identifiers
PMID41984625
PMCPMC13181795
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390